Comparison between included and non-included patients.

<p>¹One FibroTest was not reliable, and all AshTest were reliable</p><p>Comparison between included and non-included patients.</p

Performance of AshTest for the diagnosis (binary) and severity (ordinal) of alcoholic steatohepatitis (n = 123).

<p>AshTest had significant higher AUROCs than AST/ALT for all scores and lesions. NonBinROC is the Obuchowski measure, the non-binary estimate of ordinal test performance. AshTest had significant Obuchowski measures than AST/ALT for ASH scores and for PMN and Mallory.</p><p>Performance of AshTest for the diagnosis (binary) and severity (ordinal) of alcoholic steatohepatitis (n = 123).</p

Flow chart of inclusion.

<p>Flow chart of inclusion.</p

Concordance between ASH grades presumed by AshTest and by biopsy.

<p>The histological score is the sum of the 3 elementary lesion grades: Ballooning, PMN and Mallory bodies.</p><p>Concordance between ASH grades presumed by AshTest and by biopsy.</p

Area under the ROC curves (AUROC) of AshTest versus AST/ALT, Maddrey, and MELD scores.

<p>0.815 (0.639–0.910), 0.565 (0.348–0.725), 0.571 (0.448–0.730) and 0.537 (0.327–0.751) respectively, for the diagnosis of at least one histological features of alcoholic hepatitis. All comparisons were significant (P<0.01) between AshTest and AST/ALT, Maddrey and MELD scores.</p

Comparison of Area under the Receiver Operating Characteristics Curves (AUROC) for survival endpoints, between FibroTest, ActiTest, ALT, viral load, Pugh score and APRI index. N = 978.

f<p>FibroTest AUROC greater than that with ActiTest (p = 0.001), ALT (p<0.001), Viral Load (p<0.001), Pugh classification (p = 0.0025), APRI Index (p<0.001).</p>g<p>FibroTest AUROC greater than that with ActiTest (p = 0.0016), ALT (p<0.001), Viral Load (p<0.001), Pugh classification (p = 0.005), APRI Index (p<0.001).</p>h<p>FibroTest AUROC greater than that with ActiTest (p<0.001), ALT (p<0.001), Viral Load (p<0.001), Pugh classification (p = 0.002), APRI Index (p<0.001).</p

Comparison of Area under the Receiver Operating Characteristics Curves (AUROC) for survival endpoints, between FibroTest, ActiTest, ALT and viral load. N = 1074.

c<p>FibroTest AUROC greater than that with ActiTest (p<0.001), ALT (p<0.001), Viral load (p<0.001).</p>d<p>FibroTest AUROC greater than that with ActiTest (p = 0.0009), ALT (p = <0.001), Viral load (p<0.001).</p>e<p>FibroTest AUROC greater than that with ActiTest (p<0.001), ALT (p<0.001), Viral load (p<0.001).</p

4-year survival according to baseline FibroTest, viral load ALT values and treatment.

§<p>Survival of the severe fibrosis group was significantly lower than the two other groups (P<0.001).</p>§§<p>Overall survival of the severe fibrosis group, treated or not, was significantly lower than that of paired controls (p<0.05).</p>*<p>Overall survival of the 1074 HBV patients, was significantly lower than that of paired controls (p<0.05).</p>$<p>P = 0.03 vs treated.</p>£<p>P = 0.047 vs treated.</p>***<p>Survivals of the treated patients were similar to those of the non –treated in different groups of viral load (p>0.05).</p>****<p>Overall survival of the group with high viral load was lower than that of paired controls (p<0.05).</p>$*<p>Overall survival of the group with elevated ALT was lower than that of paired controls (p<0.05).</p><p>We used the manufacturers' definitions of normal FT (< = 0.27), normal AT (< = 0.29) and 3 classes for viral load in IU/ml.</p

Prognostic factors associated with survival without HBV complications or death in 1074 patients.

<p>Prognostic factors associated with survival without HBV complications or death in 1074 patients.</p

Characteristics of included patients.

<p>NP = Not performed.</p